Search
ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy
He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer...
Jun 2
State of Possible: Strand Therapeutics' Co-Founder & CEO Jake Becraft talks mRNA and getting into the clinic with the company's first program
He describes the intratumoral IL-12 program that is in the clinic today, and the preclinical progress Strand is making on its other...
Mar 26
The next generation of mRNA beyond vaccines with Strand Therapeutics
Jake Becraft describes emerging new techniques in using mRNA and gives BiotechTV a tour of Strand’s Fenway HQ to show us the R&D process.
Sep 5, 2023
.png){kind=logo}
